MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317452 | Name: Ceftibuten hydrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ceftibuten is a third-generation cephalosporin antibiotic used primarily for treating bacterial infections, particularly respiratory tract infections. Ceftibuten inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), which are essential enzymes involved in the final steps of peptidoglycan cross-linking. This leads to cell wall weakening and ultimately bacterial cell lysis. ceftibuten is bactericidal and primarily effective against Gram-negative bacteria. Bioactivity: Spectrum of Activity: Ceftibuten is particularly active against Gram-negative organisms, including Haemophilus influenzae, Moraxella catarrhalis, and Escherichia coli. It also has some activity against Gram-positive bacteria but is less effective than earlier-generation cephalosporins. β-lactamase Stability: It is resistant to hydrolysis by many β-lactamases, making it more effective against β-lactamase-producing bacteria. Oral Bioavailability: Ceftibuten is notable for its high oral bioavailability (~90%), making it effective as an oral antibiotic. Pharmacokinetics: It has a long half-life (~4-5 hours), allowing for once-daily dosing.

Chemical Structure

Ceftibuten hydrate
CAS#118081-34-8 (hydrate)

Theoretical Analysis

MedKoo Cat#: 317452

Name: Ceftibuten hydrate

CAS#: 118081-34-8 (hydrate)

Chemical Formula: C15H18N4O8S2

Exact Mass: 0.0000

Molecular Weight: 446.46

Elemental Analysis: C, 40.35; H, 4.06; N, 12.55; O, 28.67; S, 14.36

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 Weeks
50mg USD 750.00 2 Weeks
100mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
97519-39-6 (free) 118081-34-8 (hydrate) 97519-41-0 (HCl) 97518-16-6 (sodium)
Synonym
Ceftibuten Dihydrate; Ceftibuten (dihydrate); Isocef; Seftem; SCH 39720; SCH39720; SCH-39720
IUPAC/Chemical Name
(6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;dihydrate
InChi Key
SSWTVBYDDFPFAF-ODPSPGRDSA-N
InChi Code
InChI=1S/C15H14N4O6S2.2H2O/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19;;/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25);2*1H2/b6-1+;;
SMILES Code
C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O.O.O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 446.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kresken M, Körber-Irrgang B, Biedenbach DJ, Batista N, Besard V, Cantón R, García-Castillo M, Kalka-Moll W, Pascual A, Schwarz R, Van Meensel B, Wisplinghoff H, Seifert H. Comparative in vitro activity of oral antimicrobial agents against Enterobacteriaceae from patients with community-acquired urinary tract infections in three European countries. Clin Microbiol Infect. 2015 Aug 29. pii: S1198-743X(15)00805-8. doi: 10.1016/j.cmi.2015.08.019. [Epub ahead of print] PubMed PMID: 26321667. 2: Seki T, Kimura K, Reid ME, Miyazaki A, Banno H, Jin W, Wachino J, Yamada K, Arakawa Y. High isolation rate of MDR group B streptococci with reduced penicillin susceptibility in Japan. J Antimicrob Chemother. 2015 Oct;70(10):2725-8. doi: 10.1093/jac/dkv203. Epub 2015 Jul 13. PubMed PMID: 26169560. 3: Kamiya C, Kimura K, Doyama Y, Miyazaki A, Morimoto M, Banno H, Nagano N, Jin W, Wachino J, Yamada K, Arakawa Y. Ceftibuten-containing agar plate for detecting group B streptococci with reduced penicillin susceptibility (PRGBS). Diagn Microbiol Infect Dis. 2015 Aug;82(4):269-73. doi: 10.1016/j.diagmicrobio.2015.04.010. Epub 2015 May 1. PubMed PMID: 25959629. 4: Romano A, Gaeta F, Valluzzi RL, Maggioletti M, Zaffiro A, Caruso C, Quaratino D. IgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. J Allergy Clin Immunol. 2015 Sep;136(3):685-691.e3. doi: 10.1016/j.jaci.2015.03.012. Epub 2015 Apr 28. PubMed PMID: 25930196. 5: Sato T, Hara T, Horiyama T, Kanazawa S, Yamaguchi T, Maki H. Mechanism of resistance and antibacterial susceptibility in extended-spectrum β-lactamase phenotype Klebsiella pneumoniae and Klebsiella oxytoca isolated between 2000 and 2010 in Japan. J Med Microbiol. 2015 May;64(Pt 5):538-43. doi: 10.1099/jmm.0.000057. Epub 2015 Mar 26. PubMed PMID: 25813819. 6: Tsarev VN, Chuvilkin VI, Akhmedov GD, Chuvilkina EI, Gadzhiev FN, Nikitin IV. [PCR rationale for use of oral cephalosporins by oral surgery procedures]. Stomatologiia (Mosk). 2014;93(5):43-7. Russian. PubMed PMID: 25588340. 7: Demirel I, Kruse R, Önnberg A, Persson K. Ceftibuten-induced filamentation of extended spectrum beta lactamase (ESBL)-producing uropathogenic Escherichia coli alters host cell responses during an in vitro infection. Microb Pathog. 2015 Jan;78:52-62. doi: 10.1016/j.micpath.2014.11.015. Epub 2014 Nov 27. PubMed PMID: 25433242. 8: Nagano N, Nagano Y, Toyama M, Kimura K, Shibayama K, Arakawa Y. Penicillin-susceptible group B streptococcal clinical isolates with reduced cephalosporin susceptibility. J Clin Microbiol. 2014 Sep;52(9):3406-10. doi: 10.1128/JCM.01291-14. Epub 2014 Jun 11. PubMed PMID: 24920773; PubMed Central PMCID: PMC4313170. 9: Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Higuchi T, Ono T, Nishio H, Sueyoshi N, Kida K, Satoh K, Toda H, Toyokawa M, Nishi I, Sakamoto M, Akagi M, Mizutani T, Nakai I, Kofuku T, Orita T, Zikimoto T, Natsume S, Wada Y. Susceptibility of various oral antibacterial agents against extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother. 2014 Jan;20(1):48-51. doi: 10.1016/j.jiac.2013.08.004. Epub 2013 Dec 11. PubMed PMID: 24462425. 10: Keating GM. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria. Drugs. 2013 Nov;73(17):1951-66. doi: 10.1007/s40265-013-0143-y. Review. PubMed PMID: 24202878. 11: Chuvilkin VI, Chuvilkina EI, Tsarev VN, Shirokov IuE. [Preventive antibacterial treatment in oral bone augmentation procedures]. Stomatologiia (Mosk). 2013;92(3):84-7. Russian. PubMed PMID: 23752848. 12: Liu YL, Wu PS, Tsai LP, Tsai WH. Pediatric round pneumonia. Pediatr Neonatol. 2014 Dec;55(6):491-4. doi: 10.1016/j.pedneo.2013.01.014. Epub 2013 Mar 13. PubMed PMID: 23597522. 13: Perepanova TS, Kozlov RS, Dekhnich AV, Palagin IS, Shevelev AN, Volkova EM, Égamberdiev DK. [Choice of antibacterial drugs in urinary infection]. Urologiia. 2012 Mar-Apr;(2):4-8. Russian. PubMed PMID: 22876623. 14: Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J Antimicrob Chemother. 2012 Jun;67(6):1422-6. doi: 10.1093/jac/dks036. Epub 2012 Feb 14. PubMed PMID: 22334602. 15: Tärnberg M, Ostholm-Balkhed A, Monstein HJ, Hällgren A, Hanberger H, Nilsson LE. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2011 Aug;30(8):981-7. doi: 10.1007/s10096-011-1183-4. Epub 2011 Feb 6. PubMed PMID: 21298459. 16: Livermore DM, Mushtaq S, Nguyen T, Warner M. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents. 2011 May;37(5):405-9. doi: 10.1016/j.ijantimicag.2010.11.028. Epub 2011 Jan 26. PubMed PMID: 21276715. 17: Andrews M, Condren M. Once-daily amoxicillin for pharyngitis. J Pediatr Pharmacol Ther. 2010 Oct;15(4):244-8. PubMed PMID: 22477812; PubMed Central PMCID: PMC3042262. 18: Zaffanello M, Cataldi L, Franchini M, Fanos V. Evidence-based treatment limitations prevent any therapeutic recommendation for acute poststreptococcal glomerulonephritis in children. Med Sci Monit. 2010 Apr;16(4):RA79-84. Review. PubMed PMID: 20357732. 19: Kimura K, Wachino J, Kurokawa H, Suzuki S, Yamane K, Shibata N, Arakawa Y. Practical disk diffusion test for detecting group B streptococcus with reduced penicillin susceptibility. J Clin Microbiol. 2009 Dec;47(12):4154-7. doi: 10.1128/JCM.02063-08. Epub 2009 Oct 7. Erratum in: J Clin Microbiol. 2010 Mar;48(3):1016. PubMed PMID: 19812274; PubMed Central PMCID: PMC2786660. 20: Tapsall JW. Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. doi: 10.1097/QCO.0b013e328320a836. Review. PubMed PMID: 19532086.

View History

Difeterol

Difeterol